199 related articles for article (PubMed ID: 21864883)
21. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
22. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
23. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
24. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
Davidson B; Shafat I; Risberg B; Ilan N; Trope' CG; Vlodavsky I; Reich R
Gynecol Oncol; 2007 Feb; 104(2):311-9. PubMed ID: 17030350
[TBL] [Abstract][Full Text] [Related]
25. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
Givant-Horwitz V; Davidson B; Goderstad JM; Nesland JM; Tropé CG; Reich R
Gynecol Oncol; 2004 May; 93(2):517-23. PubMed ID: 15099972
[TBL] [Abstract][Full Text] [Related]
26. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
Vaksman O; Davidson B; Tropé C; Reich R
Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
[TBL] [Abstract][Full Text] [Related]
27. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
28. Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling.
Davidson B; Espina V; Steinberg SM; Flørenes VA; Liotta LA; Kristensen GB; Tropé CG; Berner A; Kohn EC
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):791-9. PubMed ID: 16467090
[TBL] [Abstract][Full Text] [Related]
29. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
30. Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions.
Kleinberg L; Flørenes VA; Nesland JM; Davidson B
Am J Clin Pathol; 2007 Sep; 128(3):389-97. PubMed ID: 17709312
[TBL] [Abstract][Full Text] [Related]
31. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
Bunkholt Elstrand M; Dong HP; Ødegaard E; Holth A; Elloul S; Reich R; Tropé CG; Davidson B
Hum Pathol; 2010 Jun; 41(6):794-804. PubMed ID: 20153512
[TBL] [Abstract][Full Text] [Related]
32. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
Davidson B; Trope' CG; Wang TL; Shih IeM
Gynecol Oncol; 2006 Dec; 103(3):814-9. PubMed ID: 16844205
[TBL] [Abstract][Full Text] [Related]
33. Expression of seprase in effusions from patients with epithelial ovarian carcinoma.
Zhang MZ; Qiao YH; Nesland JM; Trope C; Kennedy A; Chen WT; Suo ZH
Chin Med J (Engl); 2007 Apr; 120(8):663-8. PubMed ID: 17517181
[TBL] [Abstract][Full Text] [Related]
34. New determinates of disease progression and outcome in metastatic ovarian carcinoma.
Davidson B; Reich R; Trope CG; Wang TL; Shih IeM
Histol Histopathol; 2010 Dec; 25(12):1591-609. PubMed ID: 20886439
[TBL] [Abstract][Full Text] [Related]
35. Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors.
Kleinberg L; Pradhan M; Tropé CG; Nesland JM; Davidson B; Risberg B
Diagn Cytopathol; 2008 Sep; 36(9):637-44. PubMed ID: 18677760
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3 expression in primary and recurrent ovarian carcinomas.
Stadlmann S; Gueth U; Baumhoer D; Moch H; Terracciano L; Singer G
Int J Gynecol Pathol; 2007 Jul; 26(3):341-4. PubMed ID: 17581422
[TBL] [Abstract][Full Text] [Related]
37. Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma.
Faried A; Sohda M; Nakajima M; Miyazaki T; Kato H; Kuwano H
Eur J Cancer; 2004 Dec; 40(18):2804-11. PubMed ID: 15571964
[TBL] [Abstract][Full Text] [Related]
38. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
39. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
[TBL] [Abstract][Full Text] [Related]
40. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
